
## SUPPLEMENTARY FIGURES



Supplementary Figure 1. Progression-free survival (PFS) of patients with urinary cancer (A) and other cancers (B).

Variables	Disitamab Vedotin+ICIs	Disitamab Vedotin alone	P value	HR (95% CI)
All patients	34	15	- 0.45	1.39 (0.58-3.34)
Age				
<60	17	8	▶ 0.24	2.06 (0.63-6.78)
>=60	17	7	▶ 0.49	1.96 (0.31-12.57)
Sex				
Male	18	4	0.58	0.60 (0.07-4.76)
Female	16	11	0.91	0.91 (0.32-2.57)
Pathology				
Urothelial Carcinoma	18	7	▶ 0.44	1.84 (0.39-8.78)
Adenocarcinoma	10	2	0.31	0.31 (0.03-3.01)
Others	6	6	0.17	0.22 (0.02-1.92)
Metastasis		1		
Yes	6	5	▶ 0.78	1.42 (0.13-15.89)
No	28	10	0.74	0.74 (0.28-1.96)
Prior surgery				
No	12	2	▶ 0.78	1.37 (0.16-11.51)
Yes	22	13	▶ 0.2	2.04 (0.68-6.07)
Prior chemotherapy		1		
No	19	5	▶ 0.76	0.72 (0.09-5.98)
Yes	15	10	- 0.71	1.21 (0.44-3.36)
Prior radiotherapy				
No	25	10	0.51	1.44 (0.49-4.23)
Yes	9	5	0.96	0.96 (0.19-4.74)
Number of prior treatment lines		1		
0	12	5	▶ 0.95	1.06 (0.10-11.76)
1	9	1	▶ 0.96	2.47 (0.82-7.43)
>=2	23	9	0.5	0.50 (0.07-3.62)
Dosage of Disitamab Vedotin		1		
120mg, d1, q2w	28	12	- 0.43	1.24 (0.46-3.33)
Others	6	3	▶ 0.67	2.21 (0.31-15.82)
Number of treatment cycles		1		
1-3	15	6	- 0.86	0.88 (0.23-3.35)
4-8	16	5	▶ 0.41	2.04 (0.37-11.22)
>=8	3	4	0.39	60.22 (0.01-668175.28)
		0.0 1.0 2.0 3.0	4.0 5.0	
		<b>4</b>		

Supplementary Figure 2. Stratified survival analyses of the Disitamab Vedotin combined with ICIs and Disitamab Vedotin cohorts (progression-free survival).

Age>=60 vs. <60 $0.31$ Sex $0.02^*$ Female vs. Male $0.02^*$ Cancer type $0.59$ Others vs. Urinary Cancer $0.59$ Pathology $0.36 (0.01 to 15.06)$ Pathology $1.53 (0.04 to 61.08)$ Metastasis $0.65$ Yes vs. No $0.65$ Prior surgery $0.38 (0.09 to 1.64)$ Prior chemotherapy $0.94$ Yes vs. No $0.94$ Yes vs. No $0.94$ Prior radiotherapy $0.90$ Yes vs. No $0.90$ Instrument lines $1.09 (1.35 to 91.38)$
Sex 0.02* 5.15 (1.25 to 21.16)   Cancer type 0.59 0.36 (0.01 to 15.06)   Pathology 0.82 1.53 (0.04 to 61.08)   Metastasis 0.65 0.55 (0.04 to 7.62)   Prior surgery 0.19 0.38 (0.09 to 1.64)   Prior chemotherapy 0.94 0.94 (0.16 to 5.52)   Prior radiotherapy 0.90 1.08 (0.31 to 3.82)   Number of prior treatment lines 0.90 1.08 (0.31 to 3.82)
Female vs. Male 0.02* 5.15 (1.25 to 21.16)   Cancer type 0.59 0.36 (0.01 to 15.06)   Pathology 0.82 1.53 (0.04 to 61.08)   Metastasis 0.65 0.55 (0.04 to 7.62)   Yes vs. No 0.65 0.38 (0.09 to 1.64)   Prior surgery 0.19 0.38 (0.09 to 1.64)   Prior chemotherapy 0.94 0.94 (0.16 to 5.52)   Prior radiotherapy 0.90 1.08 (0.31 to 3.82)   Number of prior treatment lines 0.90 1.08 (0.31 to 3.82)
Cancer typeOthers vs. Urinary Cancer0.59Pathology0.36 (0.01 to 15.06)Pathology0.82Adenocarcinoma vs. Urothelial Cancer0.82Metastasis1.53 (0.04 to 61.08)Metastasis0.65Yes vs. No0.65Prior surgery0.38 (0.09 to 1.64)Prior chemotherapy0.94Yes vs. No0.94Prior radiotherapy0.90Yes vs. No0.90Interaction of prior treatment lines
Others vs. Urinary Cancer0.590.36 (0.01 to 15.06)PathologyAdenocarcinoma vs. Urothelial Cancer0.821.53 (0.04 to 61.08)Metastasis0.650.55 (0.04 to 7.62)Prior surgery0.190.38 (0.09 to 1.64)Prior chemotherapy0.940.94Yes vs. No0.940.94 (0.16 to 5.52)Prior radiotherapy1.08 (0.31 to 3.82)Yes vs. No0.901.08 (0.31 to 3.82)
PathologyAdenocarcinoma vs. Urothelial Cancer0.82Metastasis1.53 (0.04 to 61.08)Metastasis0.65Yes vs. No0.65Prior surgery0.38 (0.09 to 7.62)Prior chemotherapy0.19Yes vs. No0.94Yes vs. No0.94Prior radiotherapy0.94Yes vs. No0.90Prior radiotherapy1.08 (0.31 to 3.82)Number of prior treatment lines1.08 (0.31 to 3.82)
Adenocarcinoma vs. Urothelial Cancer0.821.53 (0.04 to 61.08)Metastasis
Metastasis   Yes vs. No 0.65   Prior surgery   Yes vs. No 0.19   Prior chemotherapy   Yes vs. No 0.94   Prior radiotherapy   Yes vs. No 0.94   Prior radiotherapy   Yes vs. No 0.90   Image: No 0.90   Yes vs. N
Yes vs. No 0.65 0.55 (0.04 to 7.62)   Prior surgery 0.19 0.38 (0.09 to 1.64)   Prior chemotherapy 0.94 0.94 (0.16 to 5.52)   Prior radiotherapy 0.90 1.08 (0.31 to 3.82)   Number of prior treatment lines 0.90 1.08 (0.31 to 3.82)
Prior surgery 0.19 0.38 (0.09 to 1.64)   Prior chemotherapy 0.94 0.94 (0.16 to 5.52)   Prior radiotherapy 0.90 1.08 (0.31 to 3.82)   Number of prior treatment lines 0.90 1.08 (0.31 to 3.82)
Yes vs. No 0.19 0.38 (0.09 to 1.64)   Prior chemotherapy 0.94 0.94 (0.16 to 5.52)   Prior radiotherapy 0.90 1.08 (0.31 to 3.82)   Number of prior treatment lines 0.90 1.08 (0.31 to 3.82)
Prior chemotherapy   Yes vs. No 0.94   Prior radiotherapy   Yes vs. No 0.90   Number of prior treatment lines
Yes vs. No 0.94 0.94 (0.16 to 5.52)   Prior radiotherapy 1.08 (0.31 to 3.82)   Yes vs. No 0.90 1.08 (0.31 to 3.82)   Number of prior treatment lines 1.08 (0.31 to 3.82)
Prior radiotherapy   Yes vs. No 0.90   Number of prior treatment lines
Yes vs. No0.901.08 (0.31 to 3.82)Number of prior treatment lines
Number of prior treatment lines
· · · · ·
1 vs 0 0.03* 11.09 (1.35 to 91.38)
>=2 vs. 0 0.40
Dosage
<120mg vs. 120mg, d1, q2w 0.83 1.38 (0.07 to 27.61)
Number of treatment cycles
4-8 vs. 1-3 0.69 → 1 0.75 (0.18 to 3.08)
>=8 vs. 1-3 0.18 ••••••• 0.28 (0.05 to 1.80)
Therapy
Disitamab Vedotin alone vs. Disitamab Vedotin+ICI: 0.29 $\rightarrow$ 2.32 (0.49 to 11.02)
*P<0.05
0.0 1.0 2.0 3.0 4.0 5.0

Supplementary Figure 3. Multivariate analysis of the associations between progression-free survival and clinicodemographic variables.